Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Normally when people have B-cell lymphoma that is not in complete remission, they do not immediately have another treatment. They have observation. That means their doctor closely monitors their disease with imaging tests to see if their disease is improving or worsening. If their disease gets worse, they may receive more treatment.
The current standard treatment for throat cancer that is positive for the human papillomavirus (HPV) is 7 weeks of daily radiation therapy given together with chemotherapy, but this treatment can have severe side effects. In this study, researchers are assessing significantly lower doses of radiation (3 weeks) to achieve local and regional control of the tumor with significantly fewer side effects. Treatments will be given in combination with lower doses of chemotherapy (cisplatin, carboplatin, and 5-fluorouracil) as well in people with HPV-positive throat cancer.
Researchers want to see how well a new combination of drugs works to treat low-grade serous ovarian cancer. The drugs are avutometinib, defactinib, and letrozole. The people in this study have ovarian cancer that cannot be completely removed with surgery.
Mesonephric cancer is a rare gynecologic cancer. The purpose of this study is to assess the safety and effectiveness of giving VS-6766 and defactinib together in people with advanced or recurrent mesonephric gynecologic cancers.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to find the best dose of LY4170156 to treat people with solid tumors. The people in this study have solid tumors that keep growing even after treatment. Their tumors also make a protein called FRA, which plays a role in cancer growth. The tumors treated in this study include:
The purpose of this study is to see if the combination of fianlimab, cemiplimab, and ipilimumab works well against melanoma. The people in this study have melanoma that is inoperable (cannot be taken out with surgery) or metastatic (spread). In addition, their cancer keeps growing even after treatment that included immunotherapy.
The purpose of this study is to find the best dose of AZD0120 to treat AL amyloidosis. The people in this study have AL amyloidosis that came back or does not get better with treatment.
The purpose of this study is to compare the effectiveness of lutetium (177Lu) edotreotide with standard therapies in people with neuroendocrine tumors of the stomach, intestines, or pancreas. Lutetium edotreotide binds to a protein on cancer cell surfaces called the somatostatin receptor and releases radiation to kill the cancer cell.
Researchers are assessing the cellular therapy lisocabtagene maraleucel (liso-cel) in people with primary central nervous system lymphoma (PCNSL). The people in this study have PCNSL that has not yet been treated. In addition, they cannot have autologous stem cell transplantation (ASCT). During ASCT, a patient's healthy, blood-forming cells are collected before treatment, stored, and returned after treatment with very strong chemotherapy.
